Free Trial

150,516 Shares in Bicycle Therapeutics plc (NASDAQ:BCYC) Bought by Fmr LLC

Bicycle Therapeutics logo with Medical background

FMR LLC purchased a new stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,516 shares of the company's stock, valued at approximately $3,406,000. FMR LLC owned about 0.32% of Bicycle Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the stock. Assetmark Inc. bought a new position in shares of Bicycle Therapeutics in the third quarter worth about $34,000. GAMMA Investing LLC increased its position in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company's stock valued at $46,000 after purchasing an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company's stock valued at $162,000 after purchasing an additional 2,918 shares during the period. XTX Topco Ltd acquired a new stake in Bicycle Therapeutics during the 2nd quarter valued at approximately $206,000. Finally, Crossmark Global Holdings Inc. bought a new position in shares of Bicycle Therapeutics during the 3rd quarter worth approximately $257,000. 86.15% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CAO Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares of the company's stock, valued at $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total transaction of $71,499.12. Following the transaction, the chief executive officer now directly owns 380,864 shares in the company, valued at $8,478,032.64. This trade represents a 0.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,840 shares of company stock valued at $259,128. 8.50% of the stock is owned by company insiders.

Bicycle Therapeutics Stock Down 31.3 %

Bicycle Therapeutics stock traded down $6.30 during midday trading on Friday, reaching $13.81. 5,713,477 shares of the stock traded hands, compared to its average volume of 388,037. The stock has a market cap of $953.58 million, a P/E ratio of -4.20 and a beta of 0.86. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67. The stock's fifty day moving average is $22.78 and its 200-day moving average is $22.75.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million for the quarter, compared to the consensus estimate of $6.82 million. During the same period last year, the business posted ($1.26) EPS. Bicycle Therapeutics's quarterly revenue was down 50.0% on a year-over-year basis. On average, equities analysts predict that Bicycle Therapeutics plc will post -3.05 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCYC. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Royal Bank of Canada reissued an "outperform" rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. JMP Securities reaffirmed a "market outperform" rating and set a $32.00 target price on shares of Bicycle Therapeutics in a report on Monday, September 16th. Stephens started coverage on Bicycle Therapeutics in a report on Friday, November 8th. They set an "equal weight" rating and a $25.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.75.

Check Out Our Latest Research Report on Bicycle Therapeutics

Bicycle Therapeutics Profile

(Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Read More

Institutional Ownership by Quarter for Bicycle Therapeutics (NASDAQ:BCYC)

Should you invest $1,000 in Bicycle Therapeutics right now?

Before you consider Bicycle Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.

While Bicycle Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines